Direct Inhibition of RAS Reveals the Features of Oncogenic Signaling Driven by RAS G12 and Q61 Mutations.

Saved in:
Bibliographic Details
Title: Direct Inhibition of RAS Reveals the Features of Oncogenic Signaling Driven by RAS G12 and Q61 Mutations.
Authors: Marasco M; Molecular Pharmacology Program, Memorial Sloan Kettering Cancer Center, New York, New York., Kumar D; Molecular Pharmacology Program, Memorial Sloan Kettering Cancer Center, New York, New York., Garcia Borrego S; Department of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland., Seale T; Department of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland., Maddalena G; Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.; Oncology Unit 1, Veneto Institute of Oncology-IRCCS, Padova, Italy.; Department of Surgery, Oncology and Gastroenterology, University of Padua, Padova, Italy., Mezzadra R; Department of Cancer Biology and Genetics, Memorial Sloan Kettering Cancer Center, New York, New York., Belanger K; Department of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland.; Convergence Institute, Johns Hopkins University School of Medicine, Baltimore, Maryland.; Bloomberg-Kimmel Immunology Institute, Johns Hopkins University School of Medicine, Baltimore, Maryland., Cole S; Department of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland., Perez B; Department of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland.; Convergence Institute, Johns Hopkins University School of Medicine, Baltimore, Maryland.; Bloomberg-Kimmel Immunology Institute, Johns Hopkins University School of Medicine, Baltimore, Maryland., Luan W; Department of Cancer Biology and Genetics, Memorial Sloan Kettering Cancer Center, New York, New York., Mukherjee R; Molecular Pharmacology Program, Memorial Sloan Kettering Cancer Center, New York, New York., Aricescu I; Molecular Pharmacology Program, Memorial Sloan Kettering Cancer Center, New York, New York., Markov V; Antitumour Assessment Core Facility, Memorial Sloan Kettering Cancer Center, New York, New York., Zhu Y; Antitumour Assessment Core Facility, Memorial Sloan Kettering Cancer Center, New York, New York., Arena S; Department of Oncology, University of Torino, Candiolo (TO), Italy.; Candiolo Cancer Institute, FPO-IRCCS, Candiolo (TO), Italy., Bardelli A; IFOM ETS, The AIRC Institute of Molecular Oncology, Milano, Italy.; Department of Oncology, Molecular Biotechnology Center, University of Torino, Torino, Italy., de Stanchina E; Antitumour Assessment Core Facility, Memorial Sloan Kettering Cancer Center, New York, New York., Lowe SW; Department of Cancer Biology and Genetics, Memorial Sloan Kettering Cancer Center, New York, New York., Burkhart RA; Department of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland.; Division of Hepatobiliary and Pancreatic Surgery, Johns Hopkins University School of Medicine, Baltimore, Maryland., Zimmerman JW; Department of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland.; Bloomberg-Kimmel Immunology Institute, Johns Hopkins University School of Medicine, Baltimore, Maryland., Yaeger R; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York., Kopetz SE; Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas., Rosen N; Molecular Pharmacology Program, Memorial Sloan Kettering Cancer Center, New York, New York.; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York., Misale S; Department of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland.
Source: Cancer discovery [Cancer Discov] 2025 Jul 03; Vol. 15 (7), pp. 1392-1409.
Publication Type: Journal Article
Journal Info: Publisher: American Association for Cancer Research Country of Publication: United States NLM ID: 101561693 Publication Model: Print Cited Medium: Internet ISSN: 2159-8290 (Electronic) Linking ISSN: 21598274 NLM ISO Abbreviation: Cancer Discov Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:2159-8290
DOI:10.1158/2159-8290.CD-24-0614